vs
卡博特（CBT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
卡博特的季度营收约是Royalty Pharma plc的1.4倍（$849.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 8.6%，领先25.8%），Royalty Pharma plc同比增速更快（4.8% vs -11.1%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -8.7%）
卡博特公司是总部位于美国马萨诸塞州波士顿的特种化学品和高性能材料企业，业务覆盖全球20多个国家，拥有36座生产工厂、8个研发中心及28个销售办事处，在特种材料领域具备全球领先的技术和服务能力。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CBT vs RPRX — 直观对比
营收规模更大
CBT
是对方的1.4倍
$622.0M
营收增速更快
RPRX
高出15.9%
-11.1%
净利率更高
RPRX
高出25.8%
8.6%
两年增速更快
RPRX
近两年复合增速
-8.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $849.0M | $622.0M |
| 净利润 | $73.0M | $214.2M |
| 毛利率 | 24.9% | — |
| 营业利润率 | 15.2% | 62.4% |
| 净利率 | 8.6% | 34.4% |
| 营收同比 | -11.1% | 4.8% |
| 净利润同比 | -21.5% | 2.9% |
| 每股收益（稀释后） | $1.37 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBTRPRX
| Q4 25 | $849.0M | $622.0M | ||
| Q3 25 | $899.0M | $609.3M | ||
| Q2 25 | $923.0M | $578.7M | ||
| Q1 25 | $936.0M | $568.2M | ||
| Q4 24 | $955.0M | $593.6M | ||
| Q3 24 | $1.0B | $564.7M | ||
| Q2 24 | $1.0B | $537.3M | ||
| Q1 24 | $1.0B | $568.0M |
净利润CBTRPRX
| Q4 25 | $73.0M | $214.2M | ||
| Q3 25 | $43.0M | $288.2M | ||
| Q2 25 | $101.0M | $30.2M | ||
| Q1 25 | $94.0M | $238.3M | ||
| Q4 24 | $93.0M | $208.2M | ||
| Q3 24 | $137.0M | $544.0M | ||
| Q2 24 | $109.0M | $102.0M | ||
| Q1 24 | $84.0M | $4.8M |
毛利率CBTRPRX
| Q4 25 | 24.9% | — | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 26.4% | — | ||
| Q1 25 | 25.7% | — | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 24.0% | — | ||
| Q2 24 | 25.2% | — | ||
| Q1 24 | 24.1% | — |
营业利润率CBTRPRX
| Q4 25 | 15.2% | 62.4% | ||
| Q3 25 | 15.2% | 70.1% | ||
| Q2 25 | 18.1% | 36.3% | ||
| Q1 25 | 17.3% | 94.0% | ||
| Q4 24 | 16.2% | 60.9% | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 16.9% | 50.2% | ||
| Q1 24 | 15.3% | -13.0% |
净利率CBTRPRX
| Q4 25 | 8.6% | 34.4% | ||
| Q3 25 | 4.8% | 47.3% | ||
| Q2 25 | 10.9% | 5.2% | ||
| Q1 25 | 10.0% | 41.9% | ||
| Q4 24 | 9.7% | 35.1% | ||
| Q3 24 | 13.7% | 96.3% | ||
| Q2 24 | 10.7% | 19.0% | ||
| Q1 24 | 8.2% | 0.8% |
每股收益（稀释后）CBTRPRX
| Q4 25 | $1.37 | $0.49 | ||
| Q3 25 | $0.80 | $0.67 | ||
| Q2 25 | $1.86 | $0.07 | ||
| Q1 25 | $1.69 | $0.55 | ||
| Q4 24 | $1.67 | $0.46 | ||
| Q3 24 | $2.41 | $1.21 | ||
| Q2 24 | $1.94 | $0.23 | ||
| Q1 24 | $1.49 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.0M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.6B | $9.7B |
| 总资产 | $3.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CBTRPRX
| Q4 25 | $230.0M | $618.7M | ||
| Q3 25 | $258.0M | $938.9M | ||
| Q2 25 | $239.0M | $631.9M | ||
| Q1 25 | $213.0M | $1.1B | ||
| Q4 24 | $183.0M | $929.0M | ||
| Q3 24 | $223.0M | $950.1M | ||
| Q2 24 | $197.0M | $1.8B | ||
| Q1 24 | $206.0M | $843.0M |
总债务CBTRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | $1.1B | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CBTRPRX
| Q4 25 | $1.6B | $9.7B | ||
| Q3 25 | $1.6B | $9.6B | ||
| Q2 25 | $1.5B | $9.5B | ||
| Q1 25 | $1.4B | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.4B | $10.3B | ||
| Q2 24 | $1.3B | $9.8B | ||
| Q1 24 | $1.4B | $9.9B |
总资产CBTRPRX
| Q4 25 | $3.8B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.8B | $18.3B | ||
| Q1 25 | $3.8B | $17.6B | ||
| Q4 24 | $3.6B | $18.2B | ||
| Q3 24 | $3.7B | $18.0B | ||
| Q2 24 | $3.6B | $17.7B | ||
| Q1 24 | $3.6B | $16.1B |
负债/权益比CBTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.70× | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | 0.75× | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $57.0M | — |
| 自由现金流率自由现金流/营收 | 6.7% | — |
| 资本支出强度资本支出/营收 | 8.1% | — |
| 现金转化率经营现金流/净利润 | 1.73× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $401.0M | — |
8季度趋势，按日历期对齐
经营现金流CBTRPRX
| Q4 25 | $126.0M | $827.1M | ||
| Q3 25 | $219.0M | $702.6M | ||
| Q2 25 | $249.0M | $364.0M | ||
| Q1 25 | $73.0M | $596.1M | ||
| Q4 24 | $124.0M | $742.5M | ||
| Q3 24 | $204.0M | $703.6M | ||
| Q2 24 | $207.0M | $658.2M | ||
| Q1 24 | $176.0M | $664.6M |
自由现金流CBTRPRX
| Q4 25 | $57.0M | — | ||
| Q3 25 | $155.0M | — | ||
| Q2 25 | $188.0M | — | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $112.0M | — | ||
| Q2 24 | $155.0M | — | ||
| Q1 24 | $133.0M | — |
自由现金流率CBTRPRX
| Q4 25 | 6.7% | — | ||
| Q3 25 | 17.2% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 15.3% | — | ||
| Q1 24 | 13.1% | — |
资本支出强度CBTRPRX
| Q4 25 | 8.1% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 4.2% | — |
现金转化率CBTRPRX
| Q4 25 | 1.73× | 3.86× | ||
| Q3 25 | 5.09× | 2.44× | ||
| Q2 25 | 2.47× | 12.06× | ||
| Q1 25 | 0.78× | 2.50× | ||
| Q4 24 | 1.33× | 3.57× | ||
| Q3 24 | 1.49× | 1.29× | ||
| Q2 24 | 1.90× | 6.45× | ||
| Q1 24 | 2.10× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBT
| Reinforcement Materials | $520.0M | 61% |
| Performance Chemicals | $300.0M | 35% |
| Shipping And Handling | $25.0M | 3% |
| Other Products And Services | $4.0M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
